Immunological activity and serum CEA levels following oral administration of a muramyl dipeptide (GMDP) to patients with advanced colorectal cancer

Surgical Research Communications

Volumn 18, Issue 2, 1996, Pages 137-146

  Preketes, A P ^a   King, J ^a   Bolton, E J ^a   Clingan, P R ^a   Kwan, Y L ^a   Morris, D L ^a  

^a ST GEORGE HOSPITAL   (Australia)

Author keywords

Carcinoembryonic antigen; Colorectal cancer; GMDP; Muramyl peptides

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; IMMUNOMODULATING AGENT; MURAMYL DIPEPTIDE;

ADVANCED CANCER; ARTICLE; BLOOD CHEMISTRY; CELLULAR IMMUNITY; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; GRANULOCYTE; HUMAN; IMMUNOLOGY; IMMUNOMODULATION; LYMPHOCYTE COUNT; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; T LYMPHOCYTE; THROMBOCYTE COUNT;

EID: 0029913355     PISSN: 08829233     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (0)